News coverage about Sonoma Pharmaceuticals (NASDAQ:SNOA) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sonoma Pharmaceuticals earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.2116264395866 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

A number of equities research analysts have issued reports on the company. Maxim Group set a $10.00 price target on Sonoma Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. ValuEngine downgraded Sonoma Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 1st.

Shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) opened at 5.40 on Thursday. The company has a market capitalization of $23.26 million, a P/E ratio of 2.75 and a beta of 1.28. Sonoma Pharmaceuticals has a 1-year low of $3.91 and a 1-year high of $8.25. The firm’s 50 day moving average price is $5.90 and its 200-day moving average price is $6.67.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.09). Sonoma Pharmaceuticals had a net margin of 54.36% and a negative return on equity of 44.24%. The business had revenue of $3.84 million during the quarter. Analysts expect that Sonoma Pharmaceuticals will post ($2.67) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Sonoma Pharmaceuticals (SNOA) Receives News Sentiment Rating of 0.01” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/09/14/sonoma-pharmaceuticals-snoa-receives-news-sentiment-rating-of-0-01.html.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.

Insider Buying and Selling by Quarter for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Receive News & Ratings for Sonoma Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.